Synthego — Startup Profile
CRISPR genome engineering solutions for life sciences research
HQ: Redwood City, California, USA | Founded: 2012 | Employees: 200-500 | Stage: Late Stage VC | Website: https://www.synthego.com
About
Synthego develops and commercializes CRISPR genome engineering tools, including synthetic guide RNAs, engineered cell lines, and bioinformatics software, enabling researchers in pharmaceutical companies and academic institutions to perform precise gene editing at scale. The company's platform is designed to accelerate drug discovery and therapeutic development workflows by providing standardized, high-quality genome engineering reagents and services. Its product portfolio spans synthetic RNA, cell engineering services, and software tools for CRISPR experiment design and analysis.
The Take
Synthego is a CRISPR genome engineering company that provides synthetic RNA and engineered cell solutions to pharmaceutical and academic researchers, operating in a $150B+ genomics market with modeled unit economics showing a 5x LTV/CAC ratio and 72% gross margins, though the company currently faces a zero-runway situation that raises urgent questions about its near-term viability.
Key Metrics
- Latest Valuation: Undisclosed
- Last Round: Undisclosed
- Total Funding: Undisclosed
- Headcount: 200-500
- Founded: 2012
- Est. Runway: 0 months
Funding Rounds
- Round: $200M (2021-09-01) — Wellington Management, RA Capital Management
- Round: $80M (2018-11-01) — 8VC, Menlo Ventures
Key People
- Paul Dabrowski
- Kevin Holden
Key Competitors
- Integrated DNA Technologies (IDT) —
- Thermo Fisher Scientific —
- Mammoth Biosciences —
- Editas Medicine —
Timeline Highlights
- 2023-06-01: Eclipse Platform Launch
- 2021-09-01: Series D Funding
- 2018-11-01: Series C Funding
- 2012-01-01: Company Founded
Recent News
- Synthego Raises $200M Series D to Scale CRISPR Platform (2021-09-15)
- Synthego Launches Eclipse Platform for Automated Cell Engineering (2023-06-15)
Similar Startups
- Solugen — Bio-based chemical manufacturing via a modular enzymatic platform
- Benchling — Unified R&D Cloud for life sciences
- Altos Labs — Cellular rejuvenation programming to reverse disease and transform medicine
- Colossal Biosciences — De-extinction and genetic engineering company resurrecting extinct species
- eGenesis — Genome engineering for human-compatible organ transplants
More Biotech Startups
- Altos Labs — Cellular rejuvenation programming to reverse disease and transform medicine
- Vilya — Computational biotech platform designing novel molecular structures to target disease biology
- Insitro — Machine learning-enabled drug discovery and development platform combining high-throughput biology w
- Colossal Biosciences — De-extinction and genetic engineering company resurrecting extinct species
- eGenesis — Genome engineering for human-compatible organ transplants
Browse: Home | Blog | About | All Startups A-Z | View full profile on StartupWiki